Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.
Identifieur interne : 003115 ( PubMed/Curation ); précédent : 003114; suivant : 003116Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.
Auteurs : Marie Levade [France] ; Elodie David [France] ; Cédric Garcia [France] ; Pierre-Alexandre Laurent [France] ; Sarah Cadot [France] ; Anne-Sophie Michallet [France] ; Jean-Claude Bordet [France] ; Constantine Tam ; Pierre Sié [France] ; Loïc Ysebaert [France] ; Bernard Payrastre [France]Source :
- Blood [ 1528-0020 ] ; 2014.
Descripteurs français
- KwdFr :
- Activation plaquettaire, Adhésivité plaquettaire, Antienzymes (), Collagène (), Diméthylsulfoxyde (), Facteur de von Willebrand (), Humains, Hémostase, Héparine (), Phospholipase C gamma (), Phosphorylation, Plaquettes (), Plaquettes (cytologie), Pyrazoles (), Pyrimidines (), Résistance au cisaillement, Études longitudinales.
- MESH :
- cytologie : Plaquettes.
- Activation plaquettaire, Adhésivité plaquettaire, Antienzymes, Collagène, Diméthylsulfoxyde, Facteur de von Willebrand, Humains, Hémostase, Héparine, Phospholipase C gamma, Phosphorylation, Plaquettes, Pyrazoles, Pyrimidines, Résistance au cisaillement, Études longitudinales.
English descriptors
- KwdEn :
- Blood Platelets (cytology), Blood Platelets (drug effects), Collagen (chemistry), Dimethyl Sulfoxide (chemistry), Enzyme Inhibitors (chemistry), Hemostasis, Heparin (chemistry), Humans, Longitudinal Studies, Phospholipase C gamma (chemistry), Phosphorylation, Platelet Activation, Platelet Adhesiveness, Pyrazoles (chemistry), Pyrimidines (chemistry), Shear Strength, von Willebrand Factor (chemistry).
- MESH :
- chemical , chemistry : Collagen, Dimethyl Sulfoxide, Enzyme Inhibitors, Heparin, Phospholipase C gamma, Pyrazoles, Pyrimidines, von Willebrand Factor.
- cytology : Blood Platelets.
- drug effects : Blood Platelets.
- Hemostasis, Humans, Longitudinal Studies, Phosphorylation, Platelet Activation, Platelet Adhesiveness, Shear Strength.
Abstract
The oral Bruton's tyrosine kinase inhibitor, ibrutinib, has recently demonstrated high efficiency in patients with relapsed B-cell malignancies. Occurrence of bleeding events has been reported in a subgroup of ibrutinib-treated patients. We demonstrate that ibrutinib selectively inhibits platelet signaling and functions downstream of the collagen receptor glycoprotein VI and strongly affects firm platelet adhesion on von Willebrand factor (VWF) under arterial flow. A longitudinal study of 14 patients indicated a correlation between occurrence of bleeding events and decreased platelet aggregation in response to collagen in platelet-rich plasma and firm adhesion on VWF under arterial flow. The addition of 50% untreated platelets was sufficient to efficiently reverse the effects of ibrutinib, and platelet functions recovered after treatment interruption as physiological platelet renewal occurred. These data have important clinical implications and provide a basis for hemostasis management during ibrutinib treatment.
DOI: 10.1182/blood-2014-06-583294
PubMed: 25305202
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003225
Links to Exploration step
pubmed:25305202Curation
No country items
Constantine Tam<affiliation><nlm:affiliation>Department of Hematology, Peter MacCallum Cancer Center, East Melbourne, VIC, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.</title><author><name sortKey="Levade, Marie" sort="Levade, Marie" uniqKey="Levade M" first="Marie" last="Levade">Marie Levade</name><affiliation wicri:level="1"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="David, Elodie" sort="David, Elodie" uniqKey="David E" first="Elodie" last="David">Elodie David</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Garcia, Cedric" sort="Garcia, Cedric" uniqKey="Garcia C" first="Cédric" last="Garcia">Cédric Garcia</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Laurent, Pierre Alexandre" sort="Laurent, Pierre Alexandre" uniqKey="Laurent P" first="Pierre-Alexandre" last="Laurent">Pierre-Alexandre Laurent</name><affiliation wicri:level="1"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Cadot, Sarah" sort="Cadot, Sarah" uniqKey="Cadot S" first="Sarah" last="Cadot">Sarah Cadot</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Michallet, Anne Sophie" sort="Michallet, Anne Sophie" uniqKey="Michallet A" first="Anne-Sophie" last="Michallet">Anne-Sophie Michallet</name><affiliation wicri:level="1"><nlm:affiliation>Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite</wicri:regionArea></affiliation></author><author><name sortKey="Bordet, Jean Claude" sort="Bordet, Jean Claude" uniqKey="Bordet J" first="Jean-Claude" last="Bordet">Jean-Claude Bordet</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire d'Hémostase, Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hémostase, Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon</wicri:regionArea></affiliation></author><author><name sortKey="Tam, Constantine" sort="Tam, Constantine" uniqKey="Tam C" first="Constantine" last="Tam">Constantine Tam</name><affiliation><nlm:affiliation>Department of Hematology, Peter MacCallum Cancer Center, East Melbourne, VIC, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Sie, Pierre" sort="Sie, Pierre" uniqKey="Sie P" first="Pierre" last="Sié">Pierre Sié</name><affiliation wicri:level="1"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Ysebaert, Loic" sort="Ysebaert, Loic" uniqKey="Ysebaert L" first="Loïc" last="Ysebaert">Loïc Ysebaert</name><affiliation wicri:level="1"><nlm:affiliation>Service d'Hématologie Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hématologie Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Payrastre, Bernard" sort="Payrastre, Bernard" uniqKey="Payrastre B" first="Bernard" last="Payrastre">Bernard Payrastre</name><affiliation wicri:level="1"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25305202</idno><idno type="pmid">25305202</idno><idno type="doi">10.1182/blood-2014-06-583294</idno><idno type="wicri:Area/PubMed/Corpus">003225</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003225</idno><idno type="wicri:Area/PubMed/Curation">003115</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003115</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.</title><author><name sortKey="Levade, Marie" sort="Levade, Marie" uniqKey="Levade M" first="Marie" last="Levade">Marie Levade</name><affiliation wicri:level="1"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="David, Elodie" sort="David, Elodie" uniqKey="David E" first="Elodie" last="David">Elodie David</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Garcia, Cedric" sort="Garcia, Cedric" uniqKey="Garcia C" first="Cédric" last="Garcia">Cédric Garcia</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Laurent, Pierre Alexandre" sort="Laurent, Pierre Alexandre" uniqKey="Laurent P" first="Pierre-Alexandre" last="Laurent">Pierre-Alexandre Laurent</name><affiliation wicri:level="1"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Cadot, Sarah" sort="Cadot, Sarah" uniqKey="Cadot S" first="Sarah" last="Cadot">Sarah Cadot</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Michallet, Anne Sophie" sort="Michallet, Anne Sophie" uniqKey="Michallet A" first="Anne-Sophie" last="Michallet">Anne-Sophie Michallet</name><affiliation wicri:level="1"><nlm:affiliation>Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite</wicri:regionArea></affiliation></author><author><name sortKey="Bordet, Jean Claude" sort="Bordet, Jean Claude" uniqKey="Bordet J" first="Jean-Claude" last="Bordet">Jean-Claude Bordet</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire d'Hémostase, Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hémostase, Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon</wicri:regionArea></affiliation></author><author><name sortKey="Tam, Constantine" sort="Tam, Constantine" uniqKey="Tam C" first="Constantine" last="Tam">Constantine Tam</name><affiliation><nlm:affiliation>Department of Hematology, Peter MacCallum Cancer Center, East Melbourne, VIC, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Sie, Pierre" sort="Sie, Pierre" uniqKey="Sie P" first="Pierre" last="Sié">Pierre Sié</name><affiliation wicri:level="1"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Ysebaert, Loic" sort="Ysebaert, Loic" uniqKey="Ysebaert L" first="Loïc" last="Ysebaert">Loïc Ysebaert</name><affiliation wicri:level="1"><nlm:affiliation>Service d'Hématologie Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hématologie Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Payrastre, Bernard" sort="Payrastre, Bernard" uniqKey="Payrastre B" first="Bernard" last="Payrastre">Bernard Payrastre</name><affiliation wicri:level="1"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author></analytic><series><title level="j">Blood</title><idno type="eISSN">1528-0020</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Platelets (cytology)</term><term>Blood Platelets (drug effects)</term><term>Collagen (chemistry)</term><term>Dimethyl Sulfoxide (chemistry)</term><term>Enzyme Inhibitors (chemistry)</term><term>Hemostasis</term><term>Heparin (chemistry)</term><term>Humans</term><term>Longitudinal Studies</term><term>Phospholipase C gamma (chemistry)</term><term>Phosphorylation</term><term>Platelet Activation</term><term>Platelet Adhesiveness</term><term>Pyrazoles (chemistry)</term><term>Pyrimidines (chemistry)</term><term>Shear Strength</term><term>von Willebrand Factor (chemistry)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Activation plaquettaire</term><term>Adhésivité plaquettaire</term><term>Antienzymes ()</term><term>Collagène ()</term><term>Diméthylsulfoxyde ()</term><term>Facteur de von Willebrand ()</term><term>Humains</term><term>Hémostase</term><term>Héparine ()</term><term>Phospholipase C gamma ()</term><term>Phosphorylation</term><term>Plaquettes ()</term><term>Plaquettes (cytologie)</term><term>Pyrazoles ()</term><term>Pyrimidines ()</term><term>Résistance au cisaillement</term><term>Études longitudinales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Collagen</term><term>Dimethyl Sulfoxide</term><term>Enzyme Inhibitors</term><term>Heparin</term><term>Phospholipase C gamma</term><term>Pyrazoles</term><term>Pyrimidines</term><term>von Willebrand Factor</term></keywords><keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Plaquettes</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Blood Platelets</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Platelets</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Hemostasis</term><term>Humans</term><term>Longitudinal Studies</term><term>Phosphorylation</term><term>Platelet Activation</term><term>Platelet Adhesiveness</term><term>Shear Strength</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Activation plaquettaire</term><term>Adhésivité plaquettaire</term><term>Antienzymes</term><term>Collagène</term><term>Diméthylsulfoxyde</term><term>Facteur de von Willebrand</term><term>Humains</term><term>Hémostase</term><term>Héparine</term><term>Phospholipase C gamma</term><term>Phosphorylation</term><term>Plaquettes</term><term>Pyrazoles</term><term>Pyrimidines</term><term>Résistance au cisaillement</term><term>Études longitudinales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The oral Bruton's tyrosine kinase inhibitor, ibrutinib, has recently demonstrated high efficiency in patients with relapsed B-cell malignancies. Occurrence of bleeding events has been reported in a subgroup of ibrutinib-treated patients. We demonstrate that ibrutinib selectively inhibits platelet signaling and functions downstream of the collagen receptor glycoprotein VI and strongly affects firm platelet adhesion on von Willebrand factor (VWF) under arterial flow. A longitudinal study of 14 patients indicated a correlation between occurrence of bleeding events and decreased platelet aggregation in response to collagen in platelet-rich plasma and firm adhesion on VWF under arterial flow. The addition of 50% untreated platelets was sufficient to efficiently reverse the effects of ibrutinib, and platelet functions recovered after treatment interruption as physiological platelet renewal occurred. These data have important clinical implications and provide a basis for hemostasis management during ibrutinib treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25305202</PMID><DateCreated><Year>2014</Year><Month>12</Month><Day>19</Day></DateCreated><DateCompleted><Year>2015</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2014</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0020</ISSN><JournalIssue CitedMedium="Internet"><Volume>124</Volume><Issue>26</Issue><PubDate><Year>2014</Year><Month>Dec</Month><Day>18</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.</ArticleTitle><Pagination><MedlinePgn>3991-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2014-06-583294</ELocationID><Abstract><AbstractText>The oral Bruton's tyrosine kinase inhibitor, ibrutinib, has recently demonstrated high efficiency in patients with relapsed B-cell malignancies. Occurrence of bleeding events has been reported in a subgroup of ibrutinib-treated patients. We demonstrate that ibrutinib selectively inhibits platelet signaling and functions downstream of the collagen receptor glycoprotein VI and strongly affects firm platelet adhesion on von Willebrand factor (VWF) under arterial flow. A longitudinal study of 14 patients indicated a correlation between occurrence of bleeding events and decreased platelet aggregation in response to collagen in platelet-rich plasma and firm adhesion on VWF under arterial flow. The addition of 50% untreated platelets was sufficient to efficiently reverse the effects of ibrutinib, and platelet functions recovered after treatment interruption as physiological platelet renewal occurred. These data have important clinical implications and provide a basis for hemostasis management during ibrutinib treatment.</AbstractText><CopyrightInformation>© 2014 by The American Society of Hematology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Levade</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>Elodie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Cédric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laurent</LastName><ForeName>Pierre-Alexandre</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cadot</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michallet</LastName><ForeName>Anne-Sophie</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordet</LastName><ForeName>Jean-Claude</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Laboratoire d'Hémostase, Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>Constantine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Hematology, Peter MacCallum Cancer Center, East Melbourne, VIC, Australia; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sié</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ysebaert</LastName><ForeName>Loïc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Service d'Hématologie Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Payrastre</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C551803">PCI 32765</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-34-5</RegistryNumber><NameOfSubstance UI="D003094">Collagen</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.3</RegistryNumber><NameOfSubstance UI="D051966">Phospholipase C gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>YOW8V9698H</RegistryNumber><NameOfSubstance UI="D004121">Dimethyl Sulfoxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003094" MajorTopicYN="N">Collagen</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004121" MajorTopicYN="N">Dimethyl Sulfoxide</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006487" MajorTopicYN="N">Hemostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051966" MajorTopicYN="N">Phospholipase C gamma</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015539" MajorTopicYN="N">Platelet Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010973" MajorTopicYN="N">Platelet Adhesiveness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033081" MajorTopicYN="N">Shear Strength</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014841" MajorTopicYN="N">von Willebrand Factor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25305202</ArticleId><ArticleId IdType="pii">blood-2014-06-583294</ArticleId><ArticleId IdType="doi">10.1182/blood-2014-06-583294</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003115 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003115 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25305202
|texte= Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25305202" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |